Jennison Associates
Jennison Associates LLC is a privately owned investment management firm based in New York City, founded in 1969. It primarily serves a diverse range of clients, including individuals, high-net-worth individuals, pension plans, corporations, and various organizations, providing tailored investment solutions. The firm manages over $93 billion in assets through separately managed accounts and commingled vehicles, including mutual funds and hedge funds. Jennison Associates specializes in equity, fixed income, and balanced portfolios, investing globally across public markets and alternative investments. Their investment strategy encompasses growth and value stocks, with a focus on multi-cap companies, and includes investments in dividend-paying stocks and master limited partnerships. For fixed income investments, the firm targets investment-grade securities from a wide array of issuers, including U.S. government and corporate entities. With a commitment to rigorous analysis, Jennison employs both fundamental and quantitative approaches to stock selection, supported by in-house and external research. The firm operates as a subsidiary of PGIM, Inc., and has additional offices in Waltham, Massachusetts.
Top Stages
Thomas Davis
Managing Director and Portfolio Manager, Global Equity Opportunity and International Equity Opportunity Strategies
Ubong Edemeka
Managing Director and Portfolio Manager, Income and Infrastructure and Research Analyst
Shaun Hong
Managing Director and Income and Infrastructure Portfolio Manager & Research Analyst, Global Telecommunication and Energy Infrastructure
Rebecca Irwin
Managing Director and Portfolio Manager, Global Equity and Global Sustainable Strategies and Research Analyst, consumer discretionary and consumer staples
Douglas Richardson
Managing Director and Client Portfolio Manager Global, International, Emerging Markets and Large Cap, Growth Equity Strategies
Eric Sartorius
Managing Director, Portfolio Manager for Small Cap Core and Mid Cap Growth Strategies and Research Analyst, Information Technology
27 past transactions
Electric Last Mile Solutions
Post in 2021
Electric Last Mile Solutions, incorporated in 2020 and based in Auburn Hills, Michigan, specializes in designing and manufacturing last mile delivery electric vehicles. The company aims to revolutionize commercial transportation by providing clean, connected, and customizable solutions that enhance business efficiency and profitability. Their inaugural vehicle, the Urban Delivery, is poised to be the first Class 1 commercial electric vehicle in the U.S. market.
Talkspace
Post in 2021
Talkspace is a behavioral healthcare company that provides online therapy services through its technology platform, connecting users with licensed therapists, psychologists, and psychiatrists. The platform allows for confidential communication and unlimited messaging therapy, enabling individuals to seek help for various mental health conditions without the need for in-person appointments. This approach caters to those who may find it difficult to open up in traditional therapy settings or who face financial barriers to accessing care. Talkspace serves a diverse clientele, including health plans, enterprises, and individual subscribers, generating revenue primarily from payor and direct-to-enterprise clients. The company focuses on delivering quality mental health support, aiming to improve the well-being of its users globally.
Field Trip Health
Post in 2021
Field Trip Health, founded in 2019 and headquartered in Toronto, Canada, offers straightforward, evidence‑based therapies designed to support healing and enhance individuals’ engagement with the world.
Clover Health
Venture Round in 2020
Clover Health Inc. is a health insurance company that specializes in providing Medicare Advantage plans primarily for senior citizens. Founded in 2014 and headquartered in San Francisco, California, the company operates in several states, including New Jersey, Arizona, Georgia, Pennsylvania, South Carolina, Tennessee, and Texas. Clover Health utilizes a Preferred Provider Organization (PPO) platform to enhance the quality of life for its members and their healthcare providers. The company employs patient-centered analytics and a dedicated care management team to identify potential health risks and deliver preventive care, thereby aiming to minimize avoidable spending and manage chronic diseases. Its proprietary software platform, Clover Assistant, offers personalized insights to physicians, supporting early detection and effective management of chronic conditions. Clover Health generates the majority of its revenue from its insurance segment, which includes both PPO and HMO plans.
Allogene Therapeutics
Convertible Note in 2018
Allogene Therapeutics is a clinical-stage biotech company focused on immuno-oncology, developing genetically engineered allogeneic T-cell therapies for cancer. The company builds a pipeline of off-the-shelf donor-derived CAR-T products using gene-editing and proprietary cell-manufacturing technologies to enable broader patient eligibility and scalable production. Its programs include UCART19 for relapsed or refractory acute lymphoblastic leukemia and other allogeneic CAR-T candidates targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue is primarily generated from collaborations and licensing agreements.
Syndax Pharmaceuticals
Series C in 2015
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.
Wave Life Sciences
Series B in 2015
Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines, designing, optimizing, and producing stereopure oligonucleotides through its PRISM platform. The company aims to address genetically defined diseases by reducing harmful protein expression or correcting dysfunctional proteins, employing modalities such as RNA editing, antisense silencing, and RNA interference. Its programs span neurological and neuromuscular conditions, reflecting an emphasis on central nervous system targets. Wave collaborates with Pfizer and Takeda on research, development, and commercialization of stereopure oligonucleotide therapeutics and antisense therapies. Founded in 2012 and based in Singapore, the company seeks to unlock the broader potential of RNA medicines to improve patient outcomes.
Ovid Therapeutics
Series B in 2015
Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing innovative treatments for patients with neurological disorders, particularly rare and orphan diseases affecting the brain. Founded in 2014 and headquartered in New York City, the company is advancing several drug candidates, including OV101, which is in Phase III trials for Angelman syndrome and has completed Phase II trials for fragile X syndrome. Ovid is also developing OV935, currently in Phase II trials for cyclin-dependent kinase-like 5 deficiency disorder and Dravet syndrome. Additionally, the company is exploring OV329 for infantile spasms and rare epilepsies, and OV881 as a microRNA gene therapy for Angelman syndrome. Ovid Therapeutics has established collaborations and licensing agreements with notable partners, including Takeda Pharmaceutical Company, H. Lundbeck A/S, and Angelini Pharma, to enhance its development efforts. The company aims to leverage scientific advancements to deliver safe and effective therapies that can significantly improve the quality of life for individuals affected by these challenging conditions.
Editas Medicine
Series B in 2015
Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.
GenSight Biologics
Series B in 2015
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.
Afferent Pharmaceuticals
Series C in 2015
Afferent Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, focused on developing innovative medicines for chronic pain management and neurogenic disorders. The company specializes in targeting P2X3 receptors found in nerve fibers, creating small molecule compounds designed to address conditions such as osteoarthritis, back pain, visceral pain, and neuropathy. Afferent's lead compound, AF-219, has successfully completed two Phase 1 clinical studies, positioning the company to advance its portfolio of therapeutics aimed at improving the quality of life for patients suffering from various pain-related ailments. Founded in 2009, Afferent Pharmaceuticals is dedicated to advancing the understanding and treatment of chronic pain through scientific innovation.
Cogent Biosciences
Series B in 2015
Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).
Regenxbio
Series D in 2015
Regenxbio Inc. is a clinical-stage biotechnology company focused on developing gene therapy products to address genetic disorders and enable cells to produce therapeutic proteins and antibodies. The company leverages its proprietary NAV Technology Platform, which utilizes adeno-associated virus vectors for gene delivery. Regenxbio's lead product candidate, RGX-314, is under investigation in a Phase I/IIa clinical trial for wet age-related macular degeneration. Other notable product candidates include RGX-121 and RGX-111, which are in clinical trials for mucopolysaccharidosis type II and I, respectively, as well as RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-501 for homozygous familial hypercholesterolemia. Additionally, Regenxbio licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and collaborates with Neurimmune AG to develop vectorized antibodies for neurodegenerative diseases. Founded in 2008 and headquartered in Rockville, Maryland, the company was previously known as ReGenX Biosciences, LLC before rebranding in 2014.
Dimension Therapeutics
Series B in 2015
Dimension Therapeutics, Inc. is a gene therapy company based in Cambridge, Massachusetts, specializing in the development of innovative treatments for rare and metabolic diseases associated with the liver. Founded in 2013, the company has a robust pipeline of gene therapy programs, including DTX101 and DTX201 for hemophilia B and A, respectively. Additionally, its portfolio encompasses DTX301 for ornithine transcarbamylase deficiency, DTX401 for glycogen storage disease type Ia, DTX501 for phenylketonuria, DTX701 for Wilson disease, and DTX601 for citrullinemia type I. Dimension Therapeutics collaborates with REGENX Biosciences, gaining access to a significant portfolio of patents related to adeno-associated virus (AAV) therapeutics. This collaboration supports the company's aim to advance its gene therapy platform and enhance its product development capabilities in the treatment of rare diseases. Dimension Therapeutics operates as a subsidiary of Ultragenyx Pharmaceutical Inc. since November 2017.
Natera
Series F in 2015
Natera, Inc. is a diagnostic and research company specializing in genetic testing services, particularly in the areas of preconception and prenatal diagnostics. Founded in 2003 and headquartered in San Carlos, California, Natera offers a range of products including the Panorama non-invasive prenatal test, which screens for chromosomal abnormalities in fetuses, and Vistara, a test for single-gene mutations. Additionally, the company provides Horizon carrier screening to assess carrier status for various genetic diseases, and Spectrum, which analyzes genetic conditions during in vitro fertilization. Natera's Anora product analyzes fetal chromosomes to understand miscarriage causes, while its non-invasive paternity tests determine parentage through fetal DNA analysis. The company's Signatera technology focuses on circulating tumor DNA to monitor cancer recurrence. Natera distributes its products through a direct sales force and a network of approximately 100 laboratory and distribution partners, both domestically and internationally. The company collaborates with BGI Genomics to develop genetic testing assays and has partnered with Foundation Medicine for personalized cancer monitoring assays.
Aeglea BioTherapeutics
Series B in 2015
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company based in Austin, Texas, specializing in the development of human enzyme therapeutics for rare genetic and cancer-related diseases. Founded in 2013, the company is focused on addressing unmet medical needs through innovative enzyme therapies. Its lead product candidate, pegzilarginase, is a recombinant human Arginase 1 enzyme currently undergoing a Phase III trial to assess its safety and efficacy in treating Arginase 1 deficiency. Additionally, Aeglea has a preclinical pipeline that includes several candidates targeting various metabolic disorders, such as ACN00177 for homocystinuria, AEB5100 for the degradation of plasma cystine and cysteine, and AEB2109, which focuses on methionine degradation. Aeglea BioTherapeutics aims to make significant advancements in the treatment of rare metabolic diseases through its specialized enzyme therapies.
Aduro Biotech
Series D in 2015
Aduro Biotech is a clinical-stage biopharmaceutical company focused on developing immunotherapies to harness the body's natural immune system for treating challenging diseases. Its pipeline includes ADU-S100, in Phase I/II trials for various solid tumors and head & neck cancer, and BION-1301, a monoclonal antibody in Phase I trial for IgA nephropathy.
Nivalis Therapeutics
Venture Round in 2014
Nivalis Therapeutics is a biotechnology company focused on developing innovative disease-modifying therapies aimed at cystic fibrosis (CF). The company is particularly dedicated to preserving intracellular S-nitrosoglutathione (GSNO), a naturally occurring molecule that plays a crucial role in cell signaling and is linked to the pathophysiology of CF. Its lead therapeutic candidate, N91115, specifically targets patients with the F508del mutation, which is the most prevalent mutation responsible for cystic fibrosis. Founded in 2007 and based in Boulder, Colorado, Nivalis Therapeutics aims to significantly improve the quality of life for individuals affected by cystic fibrosis and their families.
Flex Pharma
Venture Round in 2014
Flex Pharma, Inc. is a biotechnology company focused on developing and commercializing innovative treatments for muscle cramps, spasms, and spasticity related to neurological conditions and exercise-associated muscle cramps. Founded in 2014 and headquartered in Boston, Massachusetts, the company operates in two segments: Consumer Operations and Drug Development. Its lead drug candidate, FLX-787, is a dual transient receptor potential V1/A1 ion channel activator that has completed an exploratory Phase II clinical trial in Australia for patients with multiple sclerosis. Additionally, Flex Pharma offers HOTSHOT, a consumer beverage designed to prevent and treat exercise-associated muscle cramps, which is marketed through its direct-to-consumer website and third-party platforms. In 2019, Flex Pharma was acquired by Salarius Pharmaceuticals, marking a significant shift in its operational structure.
Bellicum Pharmaceuticals
Series C in 2014
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Houston, Texas, dedicated to the development of novel cellular immunotherapies for treating various cancers, including hematological malignancies and solid tumors. The company is advancing its innovative product candidates, notably BPX-601, an autologous GoCAR-T therapy targeting solid tumors that express prostate stem cell antigen, and BPX-603, a dual-switch GoCAR-T therapy aimed at tumors expressing human epidermal growth factor receptor 2. Bellicum utilizes its proprietary Chemical Induction of Dimerization technology platform, which allows for real-time control over immune system components, enhancing the efficacy and duration of therapeutic responses. Founded in 2004, Bellicum Pharmaceuticals has established collaborations with several organizations to further its research and development efforts in immunotherapy.
Otonomy
Series D in 2014
Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, specializing in the development and commercialization of therapeutics for ear-related diseases and disorders. The company offers OTIPRIO, a ciprofloxacin otic suspension designed for use during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-exposure formulation of dexamethasone for treating Ménière’s disease; OTO-313, aimed at treating tinnitus; and OTO-413, which targets cochlear synaptopathy and speech-in-noise hearing difficulties. Additionally, the company is developing OTO-510, an otoprotectant intended to prevent cisplatin-induced hearing loss, and OTO-6XX, which aims to induce hair cell regeneration for severe hearing loss. Otonomy leverages a proprietary formulation platform that allows for sustained drug exposure from a single administration, positioning itself as a leader in localized drug delivery for otic disorders. Founded in 2008, Otonomy focuses its operations primarily in the United States.
PTC Therapeutics
Private Equity Round in 2013
PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.
Puma Biotechnology
Private Equity Round in 2011
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative products aimed at improving cancer care. Founded in 2010 and headquartered in Los Angeles, California, the company primarily focuses on the treatment of various forms of cancer, particularly through its lead product, NERLYNX, an oral formulation of neratinib designed for HER2-positive breast cancer patients. Additionally, Puma is developing PB357, an irreversible tyrosine kinase inhibitor that targets the epidermal growth factor receptors HER1, HER2, and HER4. The company operates under a licensing agreement with Pfizer for the development and commercialization of its drug candidates, including oral and intravenous forms of neratinib, as well as PB357. With a commitment to enhancing treatment outcomes, Puma Biotechnology is focused on advancing its clinical programs and bringing effective therapies to market for cancer patients.
Merrimack Pharmaceuticals
Private Equity Round in 2011
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 1993. The company focuses on discovering, designing, and developing innovative therapies for the treatment of diseases, particularly in the fields of autoimmunity and cancer. Merrimack employs a systems biology approach that utilizes multidisciplinary capabilities to create functional and predictive computational models of biological systems, including cell signaling networks. By combining novel therapeutics with diagnostics, the company aims to enhance treatment efficacy and outcomes. Additionally, Merrimack engages in third-party agreements to facilitate the processing and commercialization of its products.
Chemocentryx
Series C in 2006
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company based in Mountain View, California, focusing on the development and commercialization of innovative medications for inflammatory disorders, autoimmune diseases, and cancer. The company specializes in orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors, aiming to inhibit the inappropriate immune responses associated with various diseases. Its lead drug candidate, Avacopan, is an orally-administered complement inhibitor currently in Phase III development for anti-neutrophil cytoplasmic auto-antibody-associated vasculitis and in Phase IIb trials for moderate-to-severe hidradenitis suppurativa and complement 3 glomerulopathy. Additionally, ChemoCentryx is advancing several other candidates, including CCX140, an inhibitor targeting the CCR2 receptor for diabetic nephropathy and focal segmental glomerulosclerosis, and CCX872, a selective CCR2 inhibitor in Phase Ib trials for advanced pancreatic cancer. Founded in 1996, ChemoCentryx continues to drive innovation in targeted therapies for rare and complex diseases.
Merrimack Pharmaceuticals
Series E in 2006
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, founded in 1993. The company focuses on discovering, designing, and developing innovative therapies for the treatment of diseases, particularly in the fields of autoimmunity and cancer. Merrimack employs a systems biology approach that utilizes multidisciplinary capabilities to create functional and predictive computational models of biological systems, including cell signaling networks. By combining novel therapeutics with diagnostics, the company aims to enhance treatment efficacy and outcomes. Additionally, Merrimack engages in third-party agreements to facilitate the processing and commercialization of its products.
Avanir Pharmaceuticals
Post in 2005
Avanir Pharmaceuticals is a biopharmaceutical company headquartered in Aliso Viejo, California, focused on developing innovative treatments for central nervous system disorders that present significant unmet medical needs. The company specializes in the research, development, and commercialization of novel pharmaceutical products aimed at conditions such as acute migraine, Alzheimer's disease, schizophrenia, dementia, and behavioral dysfunction. Avanir is dedicated to advancing therapies that can substantially improve the quality of life for patients and their families, reflecting its commitment to addressing serious chronic diseases and enhancing overall health outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.